Given their effectiveness and expanding range of benefits, it is no wonder that GLP-1 receptor agonists are becoming an increasingly popular choice for both doctors and patients alike
Despite their significant clinical potential, they are associated with certain limitations, including suboptimal pharmacokinetics and patient adherence challenges, necessitating the development of advanced drug delivery systems to optimize efficacy and improve compliance
The evidence for GLP-1 medications in treating NASH (the more severe form of fatty liver disease) is particularly impressive: Liraglutide achieved histological resolution of steatohepatitis in 39% of cases after 48 weeks, compared to just 9% in placebo groups 20 Patients taking liraglutide had 4.5 times higher likelihood of NASH resolution than those on placebo 20 Semaglutide demonstrated NASH resolution in 59% of participants versus 17% in placebo groups 21 We offer FibroScan technology to measure liver stiffness and fat content, helping us monitor your progress while on GLP-1 therapy
Research links processed food intake to higher body weights and weight gain
Persistent, severe, or worsening symptoms need medical review
